Simulations Plus logo

Simulations PlusNASDAQ: SLP

Profile

Sector:

Healthcare

Country:

United States

IPO:

18 June 1997

Next earnings report:

03 January 2025

Last dividends:

29 July 2024

Next dividends:

N/A
$557.47 M
-58%vs. 3y high
66%vs. sector
-54%vs. 3y high
80%vs. sector
-59%vs. 3y high
70%vs. sector
-69%vs. 3y high
71%vs. sector

Price

after hours | Fri, 01 Nov 2024 20:02:48 GMT
$27.78+$0.56(+2.06%)
$18.66 M$18.95 M
$18.66 M$843.00 K

Analysts recommendations

Institutional Ownership

SLP Latest News

Simulations Plus' Q4 Earnings Top Estimates on Solid Revenue Growth
zacks.com24 October 2024 Sentiment: POSITIVE

SLP's fiscal fourth-quarter performance is driven by healthy revenue growth across its software and services business segments.

Simulations Plus, Inc. (SLP) Q4 2024 Earnings Call Transcript
seekingalpha.com23 October 2024 Sentiment: NEUTRAL

Simulations Plus, Inc. (SLP) Q4 2024 Earnings Call Transcript

Simulations Plus (SLP) Surpasses Q4 Earnings Estimates
zacks.com23 October 2024 Sentiment: POSITIVE

Simulations Plus (SLP) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.18 per share a year ago.

Simulations Plus (SLP) Restructures Business Unit Post-Acquisitions
zacks.com26 August 2024 Sentiment: POSITIVE

Simulations Plus, Inc. SLP has streamlined its business unit and leadership structure to foster growth after recent acquisitions. These updates will be implemented on Aug 30, 2024.

Simulations Plus (SLP) Ties Up With ICCS for Chemical Safety
zacks.com12 July 2024 Sentiment: POSITIVE

Simulations Plus, Inc. SLP has entered into a partnership with the International Collaboration on Cosmetics Safety (“ICCS”) to develop a physiologically-based kinetic (PBK) read-across strategy for diverse chemicals and exposure routes (intravenous, oral and dermal) across virtual populations of humans and rodents. This collaboration aims to establish procedural workflows and guidelines for integrating these methods into animal-free safety assessments.

Simulations Plus Stock Drops 15% Despite EPS Beat
marketbeat.com05 July 2024 Sentiment: NEGATIVE

Simulations Plus NASDAQ: SLP is a small-cap healthcare technology company with a value of about $800 million. The firm has vastly underperformed the market and its sector over the last 12 months, with a total return of -7%.

Simulations Plus (SLP) Q3 Earnings & Revenues Beat Estimates
zacks.com03 July 2024 Sentiment: POSITIVE

Simulations Plus' (SLP) fiscal third-quarter revenues are driven by strength in Software and Services units.

Simulations Plus, Inc. (SLP) Q3 2024 Earnings Call Transcript
seekingalpha.com02 July 2024 Sentiment: POSITIVE

Simulations Plus, Inc. (NASDAQ:SLP ) Q3 2024 Earnings Conference Call July 2, 2024 5:00 PM ET Company Participants Lisa Fortuna - Investor Relations, Financial Profiles Shawn O'Connor - Chief Executive Officer Will Frederick - Chief Financial Officer & Chief Operating Officer Conference Call Participants Christine Rains - William Blair François Brisebois - Oppenheimer & Company Matt Hewitt - Craig-Hallum David Larsen - BTIG Operator Greetings, and welcome to the Simulations Plus Third Quarter Fiscal 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Analysts Estimate Simulations Plus (SLP) to Report a Decline in Earnings: What to Look Out for
zacks.com25 June 2024 Sentiment: NEGATIVE

Simulations Plus (SLP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Simulations Plus (SLP) Upgraded to Buy: Here's Why
zacks.com14 June 2024 Sentiment: POSITIVE

Simulations Plus (SLP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

  • 1(current)
  • 2

What type of business is Simulations Plus?

Simulations Plus, Inc. is one of the leading developers of software used for modeling and simulation in drug development and research. The company was founded in 1996. The headquarters is located in Lancaster, California (USA). Simulations Plus, Inc. has developed the following software products for pharmaceutical research and development: Modeling programs: GastroPlus; DDDPlus; MembranePlus; DILIsym, NAFLDsym. Programs based on forecasting and analysis of chemical properties: ADMET Predictor; MedChem Designer; MedChem Studio. PKPlus program designed for rapid analysis of clinical trial data and submission of regulatory documents. KIWI program providing an integrated platform for data analysis and reporting through its own secure cloud.

What sector is Simulations Plus in?

Simulations Plus is in the Healthcare sector

What industry is Simulations Plus in?

Simulations Plus is in the Health Information Services industry

What country is Simulations Plus from?

Simulations Plus is headquartered in United States

When did Simulations Plus go public?

Simulations Plus initial public offering (IPO) was on 18 June 1997

What is Simulations Plus website?

https://www.simulations-plus.com

Is Simulations Plus in the S&P 500?

No, Simulations Plus is not included in the S&P 500 index

Is Simulations Plus in the NASDAQ 100?

No, Simulations Plus is not included in the NASDAQ 100 index

Is Simulations Plus in the Dow Jones?

No, Simulations Plus is not included in the Dow Jones index

When was Simulations Plus the previous earnings report?

No data

When does Simulations Plus earnings report?

The next expected earnings date for Simulations Plus is 03 January 2025